Anthem (NASDAQ:ANTX) Insider Sells 2,826 Shares of Stock

Anthem, Inc. (NASDAQ:ANTX) insider Joshua Eizen sold 2,826 shares of the stock in a transaction on Thursday, November 5th. The stock was sold at an average price of $4.22, for a total transaction of $11,925.72. Following the completion of the sale, the insider directly owned 207,546 shares of the company’s stock, valued at $875,844.12. The trade was a 1.34% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Anthem Stock Up 1.3%

Shares of ANTX stock traded up $0.05 during mid-day trading on Friday, reaching $4.00. The company’s stock had a trading volume of 240,356 shares, compared to its average volume of 595,404. The firm has a market capitalization of $150.94 million, a PE ratio of -3.74 and a beta of -0.93. The company’s 50 day simple moving average is $4.78 and its 200-day simple moving average is $4.10. Anthem, Inc. has a 12-month low of $1.00 and a 12-month high of $7.19.

Anthem (NASDAQ:ANTX) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.18) earnings per share for the quarter.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Vivo Capital LLC purchased a new position in Anthem in the first quarter valued at about $10,785,000. Commodore Capital LP purchased a new stake in Anthem during the 1st quarter worth approximately $7,981,000. Spruce Street Capital LP purchased a new stake in Anthem during the 1st quarter worth approximately $5,576,000. Ally Bridge Group NY LLC purchased a new stake in Anthem during the 1st quarter worth approximately $1,800,000. Finally, Russell Investments Group Ltd. raised its position in shares of Anthem by 10,422.0% in the 3rd quarter. Russell Investments Group Ltd. now owns 222,225 shares of the company’s stock valued at $1,182,000 after purchasing an additional 220,113 shares in the last quarter. Institutional investors and hedge funds own 90.47% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on ANTX shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Anthem in a research note on Friday, October 2nd. Guggenheim started coverage on Anthem in a research report on Monday, July 20th. They set a “buy” rating and a $9.00 price target on the stock. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Anthem presently has an average rating of “Hold” and a consensus price target of $9.00.

Anthem Company Profile

An2 Therapeutics, Inc is a clinical-stage biopharmaceutical company that traded on the Nasdaq under the symbol ANTX. The company focused on developing novel treatments for serious infectious diseases, with its lead candidate, epetraborole, designed as an oral therapy for pulmonary disease caused by nontuberculous mycobacteria (NTM).

Epetraborole was evaluated in clinical studies involving patients with refractory Mycobacterium avium complex pulmonary disease, a difficult-to-treat infection that primarily affects the lungs.